Over the past three decades, remarkable advancements have been made in hemophilia gene therapy, culminating in the approval of Valoctocogene roxaparvovec (ROCTAVIAN, AAV‐FVIII) and Etranacogene dezaparvovec (HEMGENIX, AAV‐FIX) for patients with severe HA and HB, respectively. This evidence concerns the gene F8 and hemophilia.